Lecanemab in the treatment of early Alzheimer's disease: An observational study based on 7.0T ultra‐high field MRI

1. Lecanemab treatment in AD patients from Hunan, China, is generally safe, though its long-term efficacy requires further investigation. 2. The use of 7.0T MRI, particularly its SWI sequence, enhances monitoring of microbleeds and improves safety surveillance. Furthermore, DTI-ALPS, which reflects the glymphatic function, presents as a potential imaging marker for assessing treatment efficacy.